Immunopathological mechanisms and clinical manifestations of ocular graft-versus-host disease following hematopoietic stem cell transplantation.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
31 May 2024
31 May 2024
Historique:
received:
30
03
2024
accepted:
23
05
2024
revised:
21
05
2024
medline:
1
6
2024
pubmed:
1
6
2024
entrez:
31
5
2024
Statut:
aheadofprint
Résumé
Graft-versus-host disease is among the most common clinical complications following allogeneic hematopoietic stem cell transplantation. It causes inflammation-mediated destruction and dysfunction of various organ systems including ocular tissues in 60-90% of the patients and is termed ocular GVHD (oGVHD). In oGVHD, donor-derived T-cells recognize host antigens as foreign, resulting in immune dysregulation, inflammation and fibrosis of lacrimal glands, meibomian glands, cornea, and conjunctiva. The clinical presentation in oGVHD patients range from mild dry eye symptoms to catastrophic inflammation mediated pathological changes which can cause corneal perforation and blindness. In this review article, we provide detailed insights into the impact of mucosal barrier disruption, the afferent and efferent phases of immunological response involving activation of antigen presenting cells and T cells, respectively. We evaluate the evidence outlining the effector phase of the disease leading to cellular destruction and eventually fibrosis in patients with oGVHD. Finally, we discuss the well-established criteria for the diagnosis of oGVHD.
Identifiants
pubmed: 38822141
doi: 10.1038/s41409-024-02321-3
pii: 10.1038/s41409-024-02321-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI)
ID : R01EY024602
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Franklin RM, Kenyon KR, Tutschka PJ, Saral R, Richard Green W, Santos GW. Ocular manifestations of graft-vs-host disease. Ophthalmology. 1983;90:4–13. https://doi.org/10.1016/S0161-6420(83)34604-2 .
doi: 10.1016/S0161-6420(83)34604-2
pubmed: 6338437
Pellegrini M, Bernabei F, Barbato F, Arpinati M, Giannaccare G, Versura P, et al. Incidence, risk factors and complications of ocular graft-versus-host disease following hematopoietic stem cell transplantation. Am J Ophthalmol. 2021;227:25–34. https://doi.org/10.1016/J.AJO.2021.02.022 .
doi: 10.1016/J.AJO.2021.02.022
pubmed: 33626365
Bray LC, Carey PJ, Proctor SJ, Evans RGB, Hamilton PJ, Carey TPJ. Ocular complications of bone marrow transplantation. Britishlournal Ophthalmol. 1991;75:611–4.
Anderson NG, Regillo C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol. 2004;15:503–7. https://doi.org/10.1097/01.ICU.0000143684.22362.46 .
doi: 10.1097/01.ICU.0000143684.22362.46
pubmed: 15523196
Sinha S, Singh RB, Dohlman TH, Taketani Y, Yin J, Dana R. Prevalence and risk factors associated with corneal perforation in chronic ocular graft-versus-host-disease. Cornea. 2020. https://doi.org/10.1097/ICO.0000000000002526 .
Sinha S, Singh RB, Dohlman TH, Wang M, Taketani Y, Yin J, et al. Prevalence of persistent corneal epithelial defects in chronic ocular graft-versus-host disease. Am J Ophthalmol. 2020;218:296–303. https://doi.org/10.1016/j.ajo.2020.05.035 .
doi: 10.1016/j.ajo.2020.05.035
pubmed: 32717268
Singh RB, Yuksel E, Sinha S, Wang S, Taketani Y, Luznik Z, et al. Prevalence of neurotrophic keratopathy in patients with chronic ocular graft-versus-host disease. Ocul Surf. 2022;26:13–8. https://doi.org/10.1016/j.jtos.2022.07.001 .
doi: 10.1016/j.jtos.2022.07.001
pubmed: 35843560
Wang S, Singh RB, Yuksel E, Musayeva A, Sinha S, Taketani Y, et al. Ocular pain in ocular graft-versus-host disease patients with neurotrophic keratopathy. Ocul Surf. 2022;26:142–7. https://doi.org/10.1016/J.JTOS.2022.07.005 .
doi: 10.1016/J.JTOS.2022.07.005
pubmed: 35948166
Chen Y, Wang S, Alemi H, Dohlman T, Dana R. Immune regulation of the ocular surface. Exp Eye Res. 2022;218:109007 https://doi.org/10.1016/J.EXER.2022.109007 .
doi: 10.1016/J.EXER.2022.109007
pubmed: 35257715
pmcid: 9050918
Foulsham W, Coco G, Amouzegar A, Chauhan SK, Dana R. When clarity is crucial: regulating ocular surface immunity. Trends Immunol. 2018;39:288–301.
doi: 10.1016/j.it.2017.11.007
pubmed: 29248310
Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296 https://doi.org/10.1182/BLOOD-2011-06-364265 .
doi: 10.1182/BLOOD-2011-06-364265
pubmed: 22010102
pmcid: 3251233
Flowers MED, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214 https://doi.org/10.1182/BLOOD-2010-08-302109 .
doi: 10.1182/BLOOD-2010-08-302109
pubmed: 21263156
pmcid: 3062319
Hill GR, Ferrara JLM. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754–9. https://doi.org/10.1182/BLOOD.V95.9.2754.009K25_2754_2759 .
doi: 10.1182/BLOOD.V95.9.2754.009K25_2754_2759
pubmed: 10779417
Carapito R, Jung N, Kwemou M, Untrau M, Michel S, Pichot A, et al. Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. Blood. 2016;128:1979–86. https://doi.org/10.1182/BLOOD-2016-05-719070 .
doi: 10.1182/BLOOD-2016-05-719070
pubmed: 27549307
pmcid: 5147017
Martin PJ, Levine DM, Storer BE, Warren EH, Zheng X, Nelson SC, et al. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. Blood. 2017;129:791–8. https://doi.org/10.1182/BLOOD-2016-09-737700 .
doi: 10.1182/BLOOD-2016-09-737700
pubmed: 27872059
pmcid: 5301826
Klämbt V, Wohlfeil SA, Schwab L, Hülsdünker J, Ayata K, Apostolova P, et al. A novel function for P2Y2 in myeloid recipient-derived cells during graft-versus-host disease. J Immunol. 2015;195:5795–804. https://doi.org/10.4049/JIMMUNOL.1501357 .
doi: 10.4049/JIMMUNOL.1501357
pubmed: 26538394
Reinhardt K, Foell D, Vogl T, Mezger M, Wittkowski H, Fend F, et al. Monocyte-induced development of Th17 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease. J Immunol. 2014;193:3355–65. https://doi.org/10.4049/JIMMUNOL.1400983 .
doi: 10.4049/JIMMUNOL.1400983
pubmed: 25187661
Arafat SN, Robert MC, Abud T, Spurr-Michaud S, Amparo F, Dohlman CH, et al. Elevated neutrophil elastase in tears of ocular graft-versus-host disease patients. Am J Ophthalmol. 2017;176:46–52. https://doi.org/10.1016/J.AJO.2016.12.026 .
doi: 10.1016/J.AJO.2016.12.026
pubmed: 28073648
Mittal SK, Mashaghi A, Amouzegar A, Li M, Foulsham W, Sahu SK, et al. Mesenchymal stromal cells inhibit neutrophil effector functions in a murine model of ocular inflammation. Invest Ophthalmol Vis Sci. 2018;59:1191–8. https://doi.org/10.1167/iovs.17-23067 .
doi: 10.1167/iovs.17-23067
pubmed: 29625439
pmcid: 5837663
Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13:159–75. https://doi.org/10.1038/nri3399 .
doi: 10.1038/nri3399
pubmed: 23435331
Hülsdünker J, Ottmüller KJ, Neeff HP, Koyama M, Gao Z, Thomas OS, et al. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood. 2018;131:1858 https://doi.org/10.1182/BLOOD-2017-10-812891 .
doi: 10.1182/BLOOD-2017-10-812891
pubmed: 29463561
pmcid: 5909763
An S, Raju I, Surenkhuu B, Kwon JE, Gulati S, Karaman M, et al. Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies. Ocul Surf. 2019;17:589–614. https://doi.org/10.1016/J.JTOS.2019.03.010 .
doi: 10.1016/J.JTOS.2019.03.010
pubmed: 30965123
pmcid: 6721977
Byun YS, Yoo YS, Kang MJ, Whang WJ, Na KS, Mok JW, et al. Marked infiltration of neutrophils at the upper palpebral conjunctiva in patients with chronic graft-versus-host disease. Ocul Surf. 2019;17:295–302. https://doi.org/10.1016/J.JTOS.2018.12.007 .
doi: 10.1016/J.JTOS.2018.12.007
pubmed: 30578957
Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013;58:233–51. https://doi.org/10.1016/J.SURVOPHTHAL.2012.08.004 .
doi: 10.1016/J.SURVOPHTHAL.2012.08.004
pubmed: 23541042
Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172:7393–8. https://doi.org/10.4049/JIMMUNOL.172.12.7393 .
doi: 10.4049/JIMMUNOL.172.12.7393
pubmed: 15187116
Stenger EO, Turnquist HR, Mapara MY, Thomson AW. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood. 2012;119:5088 https://doi.org/10.1182/BLOOD-2011-11-364091 .
doi: 10.1182/BLOOD-2011-11-364091
pubmed: 22403259
pmcid: 3369606
Li H, Demetris AJ, McNiff J, Matte-Martone C, Tan HS, Rothstein DM, et al. Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J Immunol. 2012;188:3804–11. https://doi.org/10.4049/JIMMUNOL.1102795 .
doi: 10.4049/JIMMUNOL.1102795
pubmed: 22422880
Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009;114:4919–27. https://doi.org/10.1182/BLOOD-2008-10-161638 .
doi: 10.1182/BLOOD-2008-10-161638
pubmed: 19749094
Zeiser R, Blazar BR. Acute graft-versus-host disease—biologic process, prevention, and therapy. N Engl J Med. 2017;377:2167–79. https://doi.org/10.1056/NEJMRA1609337/SUPPL_FILE/NEJMRA1609337_DISCLOSURES.PDF .
doi: 10.1056/NEJMRA1609337/SUPPL_FILE/NEJMRA1609337_DISCLOSURES.PDF
pubmed: 29171820
pmcid: 6034180
Toubai T, Mathewson ND, Magenau J, Reddy P. Danger signals and graft-versus-host disease: current understanding and future perspectives. Front Immunol. 2016;7. https://doi.org/10.3389/FIMMU.2016.00539 .
Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem. 2009;284:24035–48. https://doi.org/10.1074/JBC.M109.014266 .
doi: 10.1074/JBC.M109.014266
pubmed: 19605353
pmcid: 2781998
Koyama M, Cheong M, Markey KA, Gartlan KH, Kuns RD, Locke KR, et al. Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. J Exp Med. 2015;212:1303–21. https://doi.org/10.1084/JEM.20150329 .
doi: 10.1084/JEM.20150329
pubmed: 26169940
pmcid: 4516799
Zilliox MJ, Gange WS, Kuffel G, Mores CR, Joyce C, de Bustros P, et al. Assessing the ocular surface microbiome in severe ocular surface diseases. Ocul Surf. 2020;18:706–12. https://doi.org/10.1016/J.JTOS.2020.07.007 .
doi: 10.1016/J.JTOS.2020.07.007
pubmed: 32717380
pmcid: 7905829
Riemens A, Stoyanova E, Rothova A, Kuiper J. Cytokines in tear fluid of patients with ocular graft-versus-host disease after allogeneic stem cell transplantation. Mol Vis. 2012;18:797.
pubmed: 22509110
pmcid: 3324363
Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550 https://doi.org/10.1016/S0140-6736(09)60237-3 .
doi: 10.1016/S0140-6736(09)60237-3
pubmed: 19282026
pmcid: 2735047
Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-α in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant. 2003;9:292–303. https://doi.org/10.1016/S1083-8791(03)00087-9 .
doi: 10.1016/S1083-8791(03)00087-9
pubmed: 12766879
Portero I, Gomez V, Arandojo C, Kreutzman A, Royg M, Ramirez A, et al. CCR7 as a new biomarker in graft-versus-host disease: T cells expressing the homing receptor CCR7 mediate the pathogenesis of Gvhd. Blood. 2014;124:3930 https://doi.org/10.1182/BLOOD.V124.21.3930.3930 .
doi: 10.1182/BLOOD.V124.21.3930.3930
Hill GR, Koyama M. Cytokines and costimulation in acute graft-versus-host disease. Blood. 2020;136:418 https://doi.org/10.1182/BLOOD.2019000952 .
doi: 10.1182/BLOOD.2019000952
pubmed: 32526028
pmcid: 7378458
Briones J, Novelli S, Sierra J. T-cell costimulatory molecules in acute-graft-versus host disease: therapeutic implications. Bone Marrow Res. 2011;2011:1–7. https://doi.org/10.1155/2011/976793 .
doi: 10.1155/2011/976793
Matte-Martone C, Liu J, Jain D, McNiff J, Shlomchik WD. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Blood. 2008;111:3884–92. https://doi.org/10.1182/BLOOD-2007-11-125294 .
doi: 10.1182/BLOOD-2007-11-125294
pubmed: 18223170
pmcid: 2275040
Gallo PM, Gallucci S. The Dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front Immunol. 2013;4. https://doi.org/10.3389/FIMMU.2013.00138 .
Land WG. Emerging role of innate immunity in organ transplantation part II: potential of damage-associated molecular patterns to generate immunostimulatory dendritic cells. Transpl Rev (Orlando). 2012;26:73–87. https://doi.org/10.1016/J.TRRE.2011.02.003 .
doi: 10.1016/J.TRRE.2011.02.003
Teshima T. Th1 and Th17 join forces for acute GVHD. Blood. 2011;118:4765–7. https://doi.org/10.1182/BLOOD-2011-09-377325 .
doi: 10.1182/BLOOD-2011-09-377325
pubmed: 22053173
Herretes S, Ross DB, Duffort S, Barreras H, Yaohong T, Saeed AM, et al. Recruitment of donor T cells to the eyes during ocular GVHD in recipients of MHC-matched allogeneic hematopoietic stem cell transplants. Invest Ophthalmol Vis Sci. 2015;56:2348 https://doi.org/10.1167/IOVS.14-15630 .
doi: 10.1167/IOVS.14-15630
pubmed: 25655798
pmcid: 4406104
Jardine L, Cytlak U, Gunawan M, Reynolds G, Green K, Wang XN, et al. Donor monocyte–derived macrophages promote human acute graft-versus-host disease. J Clin Invest. 2020;130:4574–86. https://doi.org/10.1172/JCI133909 .
doi: 10.1172/JCI133909
pubmed: 32453711
pmcid: 7456218
Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183:2645–56. https://doi.org/10.1084/JEM.183.6.2645 .
doi: 10.1084/JEM.183.6.2645
pubmed: 8676085
Zheng H, Matte-Martone C, Li H, Anderson BE, Venketesan S, Hung ST, et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood. 2008;111:2476–84. https://doi.org/10.1182/BLOOD-2007-08-109678 .
doi: 10.1182/BLOOD-2007-08-109678
pubmed: 18045967
pmcid: 2234071
Maeda Y, Levy RB, Reddy P, Liu C, Clouthier SG, Teshima T, et al. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood. 2005;105:2023–7. https://doi.org/10.1182/BLOOD-2004-08-3036 .
doi: 10.1182/BLOOD-2004-08-3036
pubmed: 15466930
Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood. 2001;97:2886–95. https://doi.org/10.1182/BLOOD.V97.9.2886 .
doi: 10.1182/BLOOD.V97.9.2886
pubmed: 11313285
Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA. 1999;96:9305–10. https://doi.org/10.1073/PNAS.96.16.9305 .
doi: 10.1073/PNAS.96.16.9305
pubmed: 10430938
pmcid: 17777
Wang H, Yang Y-G. The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity. Immunol Rev. 2014;258:30–44. https://doi.org/10.1111/imr.12151 .
doi: 10.1111/imr.12151
pubmed: 24517424
pmcid: 4040394
Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90 https://doi.org/10.1001/ARCHOPHTHALMOL.2011.364 .
doi: 10.1001/ARCHOPHTHALMOL.2011.364
pubmed: 22232476
pmcid: 3677724
Carreno-Galeano JT, Dohlman TH, Kim S, Yin J, Dana R. A review of ocular graft-versus-host disease: pathophysiology, clinical presentation and management. Ocul Immunol Inflamm. 2021;29:1190–9. https://doi.org/10.1080/09273948.2021.1939390 .
doi: 10.1080/09273948.2021.1939390
pubmed: 34228599
Uchino M, Ogawa Y, Kawai M, Shimada H, Kameyama K, Okamoto S, et al. Ocular complications in a child with acute graft-versus-host disease following cord blood stem cell transplantation: therapeutic challenges. Acta Ophthalmol Scand. 2006;84:545–8. https://doi.org/10.1111/J.1600-0420.2006.00658.X .
doi: 10.1111/J.1600-0420.2006.00658.X
pubmed: 16879579
Hayashi S, Shimizu E, Uchino M, Yazu H, Aketa N, Tsubota K, et al. The overlap syndrome: a case report of chronic graft-versus-host disease after the development of a pseudomembrane. Cornea. 2021;40:1188 https://doi.org/10.1097/ICO.0000000000002593 .
doi: 10.1097/ICO.0000000000002593
pubmed: 33284161
Yang X, Yang J, Xing X, Wan L, Li M. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther. 2014;16:R4 https://doi.org/10.1186/AR4430 .
doi: 10.1186/AR4430
pubmed: 24398084
pmcid: 3979142
Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, et al. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017;2. https://doi.org/10.1172/JCI.INSIGHT.92111 .
Chen Y, Chauhan SK, Soo Lee H, Saban DR, Dana R. Chronic dry eye disease is principally mediated by effector memory Th17 cells. Mucosal Immunol. 2014;7:38 https://doi.org/10.1038/MI.2013.20 .
doi: 10.1038/MI.2013.20
pubmed: 23571503
Nurieva RI, Chung Y. Understanding the development and function of T follicular helper cells. Cell Mol Immunol. 2010;7:190 https://doi.org/10.1038/CMI.2010.24 .
doi: 10.1038/CMI.2010.24
pubmed: 20383172
pmcid: 4002918
Mitsdoerffer M, Lee Y, Jäger A, Kim HJ, Korn T, Kolls JK, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci USA. 2010;107:14292–7. https://doi.org/10.1073/PNAS.1009234107/SUPPL_FILE/PNAS.201009234SI.PDF .
doi: 10.1073/PNAS.1009234107/SUPPL_FILE/PNAS.201009234SI.PDF
pubmed: 20660725
pmcid: 2922571
Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28:454 https://doi.org/10.1016/J.IMMUNI.2008.03.004 .
doi: 10.1016/J.IMMUNI.2008.03.004
pubmed: 18400188
pmcid: 3424508
Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JLM. Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood. 2003;102:429–35. https://doi.org/10.1182/BLOOD-2003-01-0266 .
doi: 10.1182/BLOOD-2003-01-0266
pubmed: 12663438
Matsuoka KI, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5:179ra43 https://doi.org/10.1126/SCITRANSLMED.3005265 .
doi: 10.1126/SCITRANSLMED.3005265
pubmed: 23552371
pmcid: 3686517
Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119:1570 https://doi.org/10.1182/BLOOD-2011-07-364414 .
doi: 10.1182/BLOOD-2011-07-364414
pubmed: 22072556
pmcid: 3286218
Hu B, Qiu Y, Hong J. Tear cytokine levels in the diagnosis and severity assessment of ocular chronic graft-versus-host disease(GVHD). Ocul Surf. 2020;18:298–304. https://doi.org/10.1016/J.JTOS.2019.12.005 .
doi: 10.1016/J.JTOS.2019.12.005
pubmed: 31954196
Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438–510. https://doi.org/10.1016/J.JTOS.2017.05.011 .
doi: 10.1016/J.JTOS.2017.05.011
pubmed: 28736340
Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol. 2011;300:G723 https://doi.org/10.1152/AJPGI.00414.2010 .
doi: 10.1152/AJPGI.00414.2010
pubmed: 21292997
pmcid: 3302189
Fabre T, Kared H, Friedman SL, Shoukry NH. IL-17A enhances the expression of pro-fibrotic genes through upregulation of the TGF-β receptor on hepatic stellate cells in a JNK-dependent manner. J Immunol. 2014;193:3925 https://doi.org/10.4049/JIMMUNOL.1400861 .
doi: 10.4049/JIMMUNOL.1400861
pubmed: 25210118
Ogawa Y, Razzaque MS, Kameyama K, Hasegawa G, Shimmura S, Kawai M, et al. Role of heat shock protein 47, a collagen-binding chaperone, in lacrimal gland pathology in patients with cGVHD. Invest Ophthalmol Vis Sci. 2007;48:1079–86. https://doi.org/10.1167/iovs.06-0601 .
doi: 10.1167/iovs.06-0601
pubmed: 17325149
van Megen KM, van ’t Wout EJT, Motta JL, Dekker B, Nikolic T, Roep BO. Activated mesenchymal stromal cells process and present antigens regulating adaptive immunity. Front Immunol. 2019;10:694 https://doi.org/10.3389/FIMMU.2019.00694/BIBTEX .
doi: 10.3389/FIMMU.2019.00694/BIBTEX
pubmed: 31001285
pmcid: 6457321
Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499–506. https://doi.org/10.1182/BLOOD-2007-02-069716 .
doi: 10.1182/BLOOD-2007-02-069716
pubmed: 17664353
Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13:392–402. https://doi.org/10.1016/J.STEM.2013.09.006 .
doi: 10.1016/J.STEM.2013.09.006
pubmed: 24094322
Ogawa Y, Kodama H, Kameyama K, Yamazaki K, Yasuoka H, Okamoto S, et al. Donor fibroblast chimerism in the pathogenic fibrotic lesion of human chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2005;46:4519–27. https://doi.org/10.1167/IOVS.05-0227 .
doi: 10.1167/IOVS.05-0227
pubmed: 16303943
Ogawa Y, Morikawa S, Okano H, Mabuchi Y, Suzuki S, Yaguchi T, et al. MHC-compatible bone marrow stromal/stem cells trigger fibrosis by activating host T cells in a scleroderma mouse model. Elife. 2016;5. https://doi.org/10.7554/ELIFE.09394 .
Mittal SK, Cho WK, Elbasiony E, Guan Y, Foulsham W, Chauhan SK. Mesenchymal stem cells augment regulatory T cell function via CD80-mediated interactions and promote allograft survival. Am J Transpl. 2022. https://doi.org/10.1111/AJT.17001 .
Mittal SK, Omoto M, Amouzegar A, Sahu A, Rezazadeh A, Katikireddy KR, et al. Restoration of corneal transparency by mesenchymal stem cells. Stem Cell Rep. 2016;7:583–90. https://doi.org/10.1016/J.STEMCR.2016.09.001 .
doi: 10.1016/J.STEMCR.2016.09.001
Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, Martín García E, Sánchez-Guijo F, Argüeso P, et al. Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. Ocul Surf. 2019;17:285–94. https://doi.org/10.1016/J.JTOS.2019.01.001 .
doi: 10.1016/J.JTOS.2019.01.001
pubmed: 30630121
Sánchez-Abarca LI, Hernández-Galilea E, Lorenzo R, Herrero C, Velasco A, Carrancio S, et al. Human bone marrow stromal cells differentiate into corneal tissue and prevent ocular graft-versus-host disease in mice. Cell Transpl. 2015;24:2423–33. https://doi.org/10.3727/096368915X687480 .
doi: 10.3727/096368915X687480
Tatematsu Y, Ogawa Y, Shimmura S, Dogru M, Yaguchi S, Nagai T, et al. Mucosal microvilli in dry eye patients with chronic GVHD. Bone Marrow Transpl. 2012;47:416–25. https://doi.org/10.1038/BMT.2011.89 .
doi: 10.1038/BMT.2011.89
Ogawa Y, Shimmura S, Kawakita T, Yoshida S, Kawakami Y, Tsubota K. Epithelial mesenchymal transition in human ocular chronic graft-versus-host disease. Am J Pathol. 2009;175:2372 https://doi.org/10.2353/AJPATH.2009.090318 .
doi: 10.2353/AJPATH.2009.090318
pubmed: 19893038
pmcid: 2789626
Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014;7:re8 https://doi.org/10.1126/SCISIGNAL.2005189 .
doi: 10.1126/SCISIGNAL.2005189
pubmed: 25249658
pmcid: 4372086
Sivaraman KR, Jivrajka RV, Soin K, Bouchard CS, Movahedan A, Shorter E, et al. Superior limbic keratoconjunctivitis-like inflammation in patients with chronic graft-versus-host disease. Ocular Surface. 2016;14. https://doi.org/10.1016/j.jtos.2016.04.003 .
Espana EM, Shah S, Santhiago MR, Singh AD. Graft versus host disease: clinical evaluation, diagnosis and management. Graefes Arch Clin Exp Ophthalmol. 2013;251. https://doi.org/10.1007/s00417-013-2301-z .
Suzuki M, Usui T, Kinoshita N, Yamagami S, Amano S. A case of sterile corneal perforation after bone marrow transplantation [16]. Eye. 2007. https://doi.org/10.1038/sj.eye.6702420 .
Yeh PT, Hou YC, Lin WC, Wang IJ, Hu FR. Recurrent corneal perforation and acute calcareous corneal degeneration in chronic graft-versus-host disease. J Formos Med Assoc. 2006;105:334–9. https://doi.org/10.1016/s0929-6646(09)60125-x .
doi: 10.1016/s0929-6646(09)60125-x
pubmed: 16618614
Inagaki E, Ogawa Y, Matsumoto Y, Kawakita T, Shimmura S, Tsubota K. Four cases of corneal perforation in patients with chronic graft-versus-host disease. Mol Vis. 2011;17:598–606.
pubmed: 21386923
pmcid: 3049733
Yoshida A, Kawano YI, Kato K, Yoshida S, Yoshikawa H, Muta T, et al. Apoptosis in perforated cornea of a patient with graft-versus-host disease. Can J Ophthalmol. 2006. https://doi.org/10.1016/S0008-4182(06)80010-4 .
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389–401. https://doi.org/10.1016/J.BBMT.2014.12.001 . e1
doi: 10.1016/J.BBMT.2014.12.001
Pathak M, Diep PP, Lai X, Brinch L, Ruud E, Drolsum L. Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation. Bone Marrow Transpl. 2018;53:863 https://doi.org/10.1038/S41409-018-0090-Z .
doi: 10.1038/S41409-018-0090-Z
Ogawa Y, Kim SK, Dana R, Clayton J, Jain S, Rosenblatt MI, et al. International chronic ocular graft-vs-host-disease (GVHD) consensus group: proposed diagnostic criteria for chronic GVHD (Part I). Sci Rep. 2013;3. https://doi.org/10.1038/SREP03419 .
Dietrich-Ntoukas T, Cursiefen C, Westekemper H, Eberwein P, Reinhard T, Bertz H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: Report from the German-Austrian-Swiss consensus conference on clinical practice in chronic GVHD. Cornea. 2012;31:299–310. https://doi.org/10.1097/ICO.0B013E318226BF97 .
doi: 10.1097/ICO.0B013E318226BF97
pubmed: 22157574
Li AJ, Martinez-Guasch F, Sajjan S, Cao X, Atanackovic D, Sunshine S. Tear cytokine profiling for ocular graft versus host disease utilizing a new multiplex assay. J Immunol. 2023;210. https://doi.org/10.4049/jimmunol.210.supp.173.41 .
Sunshine SB, Li A, Gausch FM, Cao X, Atanackovic D. 383 a pilot study of tear cytokine profiling in a patient with ocular graft versus host disease. J Clin Transl Sci. 2023;7. https://doi.org/10.1017/cts.2023.419 .